Sanofi and Regeneron Pharmaceuticals have entered a revised agreement for the development of novel cancer treatments.
The revisions build upon the original agreement that was signed in 2015. It will enable the companies to develop antibody programmes BCMAxCD3 and MUC16xCD3.
Go deeper with GlobalData
Sanofi agreed to provide $462m as part of a balance of payments under the original agreement. It will also pay $120m in development costs and a termination fee for the other programmes under the original agreement.
In addition, Sanofi will take responsibility for the development and commercialisation of BCMAxCD3 projects, as well as provide funding for development costs.
Regeneron has agreed to pay up to $70m for the development of BCMAxCD3 and up to $50m to develop MUC16xCD3 for mucin-16 expressing cancers. It also agreed to reimburse up to 50% of its share of collaboration profits.
Based in France, Sanofi is a pharmaceutical company focused on developing medicines for human health, while Regeneron Pharmaceuticals is a US-based biotechnology company engaged in neurotrophic factors. Both the companies have agreed to share global profits generated from the project equally.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataBiogen has entered a strategic collaboration with C4 Therapeutics for the development and marketing of treatments for neurological and Alzheimer’s diseases.
The companies will focus on the development of novel targets using C4 Therapeutics’ protein degradation platform.
Biogen will make an upfront payment of up to $415m along with potential milestone payments and future royalties.
C4 Therapeutics is a pharmaceutical company focused on the development of targeted protein degradation therapeutics, while Biogen is a biotechnology company engaged in developing treatments for neurodegenerative, hematologic, and autoimmune diseases.
Both the companies involved in the deal are based in the US.
Janssen Pharmaceuticals and Locus Biosciences have entered a collaboration and license agreement for the development of clustered regularly interspaced short palindromic repeats (CRISPR) products.
The companies will develop and commercialise CRISPR-Cas3-enhanced bacteriophage (crPhage) candidates.
Janssen has agreed to make an initial payment of $20m to Locus and up to $798m in potential development and commercial milestones and royalties on sales, as part of the agreement.
Based in the US, Locus Biosciences is a biotechnology company engaged in developing CRISPR-engineered bacteriophage products, while Janssen Pharmaceuticals is a Belgium-based pharmaceutical company focused on providing medicines for several therapeutic areas.
CytoReason has entered a collaboration agreement with Pfizer to create cell-based models of the immune system.
Pfizer has agreed to provide CytoReason with access fees, research support, and success-based payments, while CytoReason will work on Pfizer’s data and integrate it into an immune system model, under the agreement.
Based in the US, Pfizer is a pharmaceutical company focused on developing innovative medicines for brain disorders, while CytoReason is an Israel-based biodata company engaged in developing cancer immunotherapy solutions.
Jazz Pharmaceuticals has signed a collaboration agreement with Codiak Biosciences for the development of cancer therapies through engineering exosomes.
Codiak has provided a license to drug candidates for haematological malignancies and solid tumours developed using its trademarked engEx precision engineering platform to Jazz, under the agreement.
Jazz has agreed to make an upfront payment of $56m to Codiak along with pre-clinical development milestone-based payments of up to $20m.
Codiak will be responsible for the pre-clinical and early clinical development of the therapeutic candidates, while Jazz will perform Phase I/II studies and will be responsible for regulatory submissions and marketing.
Based in the US, Codiak Biosciences is focused on the development of exosome for therapeutics and cancer diagnoses, while Jazz Pharmaceuticals is an Ireland-based biopharmaceutical company engaged in the development of treatments for cataplexy and excessive daytime sleepiness.
